BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 2162240)

  • 1. A prospective trial of recombinant human interferon alpha 2B in previously untreated patients with hepatocellular carcinoma. The Gastrointestinal Tumor Study Group.
    Cancer; 1990 Jul; 66(1):135-9. PubMed ID: 2162240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Similar effects of recombinant interferon-alpha-2b and natural interferon-alpha when combined with intra-arterial 5-fluorouracil for the treatment of advanced hepatocellular carcinoma.
    Uka K; Aikata H; Takaki S; Miki D; Jeong SC; Hiramatsu A; Kodama H; Shirakawa H; Kawakami Y; Takahashi S; Toyota N; Ito K; Chayama K
    Liver Int; 2007 Nov; 27(9):1209-16. PubMed ID: 17919232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term results of a randomized, observation-controlled, phase III trial of adjuvant interferon Alfa-2b in hepatocellular carcinoma after curative resection.
    Chen LT; Chen MF; Li LA; Lee PH; Jeng LB; Lin DY; Wu CC; Mok KT; Chen CL; Lee WC; Chau GY; Chen YS; Lui WY; Hsiao CF; Whang-Peng J; Chen PJ;
    Ann Surg; 2012 Jan; 255(1):8-17. PubMed ID: 22104564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. No synergistic activity of epirubicin and interferon-alpha 2b in the treatment of hepatocellular carcinoma.
    Bokemeyer C; Kynast B; Harstrick A; Laage E; Schmoll E; von Wussow P; Schmoll HJ
    Cancer Chemother Pharmacol; 1995; 35(4):334-8. PubMed ID: 7828277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferon therapy for hepatocellular carcinoma patients with low HCV-RNA levels.
    Miyaguchi S; Watanabe T; Takahashi H; Nakamura M; Saito H; Ishii H
    Hepatogastroenterology; 2002; 49(45):724-9. PubMed ID: 12063979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma.
    Lo CM; Liu CL; Chan SC; Lam CM; Poon RT; Ng IO; Fan ST; Wong J
    Ann Surg; 2007 Jun; 245(6):831-42. PubMed ID: 17522506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant interferon alfa 2b therapy in a patient with metastatic hepatocellular carcinoma.
    Yuen MF; Hon C; Hui CK; Siu CW; Lai CL
    J Clin Gastroenterol; 2002 Sep; 35(3):272-5. PubMed ID: 12192207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of hepatocellular carcinoma with recombinant leucocyte interferon: a pilot study.
    Sachs E; Di Bisceglie AM; Dusheiko GM; Song E; Lyons SF; Schoub BD; Kew MC
    Br J Cancer; 1985 Jul; 52(1):105-9. PubMed ID: 2990514
    [No Abstract]   [Full Text] [Related]  

  • 9. Recombinant interferon-alpha in inoperable hepatocellular carcinoma: a randomized controlled trial.
    Lai CL; Lau JY; Wu PC; Ngan H; Chung HT; Mitchell SJ; Corbett TJ; Chow AW; Lin HJ
    Hepatology; 1993 Mar; 17(3):389-94. PubMed ID: 8383088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival.
    Shiratori Y; Ito Y; Yokosuka O; Imazeki F; Nakata R; Tanaka N; Arakawa Y; Hashimoto E; Hirota K; Yoshida H; Ohashi Y; Omata M;
    Ann Intern Med; 2005 Jan; 142(2):105-14. PubMed ID: 15657158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant alpha 2 interferon is superior to doxorubicin for inoperable hepatocellular carcinoma: a prospective randomised trial.
    Lai CL; Wu PC; Lok AS; Lin HJ; Ngan H; Lau JY; Chung HT; Ng MM; Yeoh EK; Arnold M
    Br J Cancer; 1989 Dec; 60(6):928-33. PubMed ID: 2557881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus.
    Shiratori Y; Shiina S; Teratani T; Imamura M; Obi S; Sato S; Koike Y; Yoshida H; Omata M
    Ann Intern Med; 2003 Feb; 138(4):299-306. PubMed ID: 12585827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of unresectable hepatocellular carcinoma with a combination of human recombinant alpha-2b interferon and doxorubicin: results of a pilot study.
    Lotz JP; Grange JD; Hannoun L; Boudghene F; Amiot X; Lamarque D; Andre T; Esteso A; Bellaiche A; Bouleuc C
    Eur J Cancer; 1994; 30A(9):1319-25. PubMed ID: 7528030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of epidemic Kaposi's sarcoma with a combination of interferon-alpha 2b and etoposide.
    Krigel RL; Slywotzky CM; Lonberg M; Green MD; Andes WA; Kempf R; Gupta S; Grace W; Spiegel RJ; Muggia FM
    J Biol Response Mod; 1988 Aug; 7(4):359-64. PubMed ID: 3049944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic efficacy of combination therapy with intra-arterial 5-fluorouracil and systemic pegylated interferon α-2b for advanced hepatocellular carcinoma with portal venous invasion.
    Kasai K; Ushio A; Kasai Y; Sawara K; Miyamoto Y; Oikawa K; Kuroda H; Takikawa Y; Suzuki K
    Cancer; 2012 Jul; 118(13):3302-10. PubMed ID: 22072099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II trial of recombinant alpha-2b interferon in the treatment of metastatic skin melanoma.
    Sertoli MR; Bernengo MG; Ardizzoni A; Brunetti I; Falcone A; Vidili MG; Cusimano MP; Appino A; Doveil G; Fortini C
    Oncology; 1989; 46(2):96-8. PubMed ID: 2710482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effective treatment for advanced hepatocellular carcinoma with portal venous invasion using a combination therapy of intra-arterial 5-fluorouracil and subcutaneous pegylated-interferon-alpha-2b.
    Mawatari H; Kirikoshi H; Yoneda M; Higurashi T; Fujita K; Saito S; Inamori M; Takahashi H; Abe Y; Kubota K; Nakajima A
    Hepatogastroenterology; 2008; 55(86-87):1776-7. PubMed ID: 19102391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I study of recombinant leukocyte A interferon (IFN-alpha 2A, Roferon-A) with doxorubicin in advanced malignant disease.
    Creagan ET; Frytak S; Long HJ; Kvols LK
    Cancer; 1989 Sep; 64(5):1034-7. PubMed ID: 2474365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka Hepatocellular Carcinoma Prevention Study Group.
    Imai Y; Kawata S; Tamura S; Yabuuchi I; Noda S; Inada M; Maeda Y; Shirai Y; Fukuzaki T; Kaji I; Ishikawa H; Matsuda Y; Nishikawa M; Seki K; Matsuzawa Y
    Ann Intern Med; 1998 Jul; 129(2):94-9. PubMed ID: 9669992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatic arterial infusion chemotherapy in combination with pegylated interferon-α-2b for advanced hepatocellular carcinoma.
    Okita K; Yamasaki T; Hamabe S; Saeki I; Harima Y; Terai S; Sakaida I
    Hepatogastroenterology; 2012; 59(114):533-7. PubMed ID: 22353519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.